Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase inhibitor relebactam – has been cleared by the FDA for adults with ...
Merck & Co/MSD’s three-drug antibiotic Recarbrio ... The new drug combines the active ingredients in MSD’s broad-spectrum antibiotic Primaxin (imipenem/cilastatin) with a new beta lactamase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback